Filter Results:
(269)
Show Results For
- All HBS Web (343)
- Faculty Publications (227)
Show Results For
- All HBS Web (343)
- Faculty Publications (227)
Sort by
- October 2007 (Revised July 2013)
- Case
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech
By: Robert F. Higgins, Sophie LaMontagne and Brent Kazan
In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates into development. However, several questions related to... View Details
Keywords: Philanthropy; Philanthropy Funding; Innovation; Funding Model; Venture Capital; Partners and Partnerships; Financing and Loans; Investment Funds; Acquisition; Philanthropy and Charitable Giving; Pharmaceutical Industry; Pharmaceutical Industry; San Diego
Higgins, Robert F., Sophie LaMontagne, and Brent Kazan. "Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech." Harvard Business School Case 808-005, October 2007. (Revised July 2013.)
- fall 2007
- Article
Pharmaceutical Regulation in the United States and Europe
By: Arthur A. Daemmrich
Daemmrich, Arthur A. "Pharmaceutical Regulation in the United States and Europe." Focus on Law Studies 23, no. 1 (fall 2007): 8–11.
- 2009
- Article
Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era
By: Arthur A. Daemmrich
This article presents a case study of the rise of Pfizer as a leading pharmaceutical company, with a focus on changing relationships between manufacturing technology and R&D between the mid-1940s and the mid-1960s. Pfizer first moved into pharmaceuticals through... View Details
Keywords: Research and Development; Production; Technology; Transformation; Relationships; Success; Organizations; Programs; Chemicals; Alignment; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Synthesis by Microbes or Chemists? Pharmaceutical Research and Manufacturing in the Antibiotic Era." History and Technology 23, no. 3 (2009): 237–256.
- March 2001 (Revised September 2002)
- Case
Merck Latin America (C): Brazil
By: Michael Beer and James Weber
Examines Merck's change effort in Brazil from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Brazil
Beer, Michael, and James Weber. "Merck Latin America (C): Brazil." Harvard Business School Case 401-031, March 2001. (Revised September 2002.)
- March 2001 (Revised September 2002)
- Case
Merck Latin America (D): Mexico
By: Michael Beer and James Weber
Examines Merck's change effort in Mexico from the perspective of the local employees. View Details
Keywords: Change Management; Cross-Cultural and Cross-Border Issues; Multinational Firms and Management; Employees; Operations; Perspective; Pharmaceutical Industry; Mexico
Beer, Michael, and James Weber. "Merck Latin America (D): Mexico." Harvard Business School Case 401-032, March 2001. (Revised September 2002.)
- 2009
- Working Paper
Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
By: Arthur Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Governing Rules, Regulations, and Reforms; Health Disorders; Health Testing and Trials; Power and Influence; Competitive Strategy; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur. "Where Is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location." Harvard Business School Working Paper, No. 09-118, April 2009.
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Geographic Location; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Demand and Consumers; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- 2007
- Article
Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation
By: Arthur A. Daemmrich
In the wake of Vioxx, Avandia, and other recent prominent cases of drugs found to cause side effects after marketing, the safety of pharmaceuticals has come to the forefront of American public policy. Press attention, congressional investigations, and legislative... View Details
Keywords: Brands and Branding; Policy; Risk Management; Government Legislation; Risk and Uncertainty; Goals and Objectives; Customers; Pharmaceutical Industry; Pharmaceutical Industry; United States
Daemmrich, Arthur A. "Pharmacovigilance and the Missing Denominator: The Changing Context of Pharmaceutical Risk Mitigation." Pharmacy in History 49, no. 2 (2007): 61–75.
- 8 Mar 2012
- Other Presentation
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health View Details
Porter, Michael E. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Creating Shared Value in Global Health, FSG, New York City, NY, United States , March 8, 2012.
- 20 May 2013
- Op-Ed
Making America an Industrial Powerhouse Again
talent pool in the US biomedical field that is second to none. And the only way to get that talent is for companies-both domestic and foreign-to do their R&D here. That's why pharmaceutical and biotechnology companies from around the... View Details
- 22 Apr 2009
- Working Paper Summaries
Where is the Pharmacy to the World? International Regulatory Variation and Pharmaceutical Industry Location
- 2014
- Working Paper
The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories
By: Francesca Lazzeri and Gary P. Pisano
Scholars and practitioners alike now recognize that a firm's capacity to assimilate and use know-how from external sources—what Cohen and Levinthal (1990) called "absorptive capacity"—plays a central role in innovation performance. In recent years, a common strategy... View Details
Keywords: Geographic Location; Industry Clusters; Knowledge Acquisition; Pharmaceutical Industry; San Francisco; San Diego; Massachusetts
Lazzeri, Francesca, and Gary P. Pisano. "The Organizational and Geographic Drivers of Absorptive Capacity: An Empirical Analysis of Pharmaceutical R&D Laboratories." Harvard Business School Working Paper, No. 14-098, April 2014.
- Article
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
By: Ariel Dora Stern, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup and Ernst R. Berndt
Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the U.S. and worldwide. Against this backdrop, many look to the expanding market for biosimilars—follow-on products to biologic drugs—as a vehicle for controlling... View Details
Keywords: Pharmaceuticals; Drug Spending; Drug Pricing; Health Care and Treatment; Spending; Price; Markets; Cost Management; United States
Stern, Ariel Dora, Jacqueline L. Chen, Melissa Ouellet, Mark R. Trusheim, Zeid El-Kilani, Amber Jessup, and Ernst R. Berndt. "Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users." Health Affairs 40, no. 6 (June 2021): 989–999.
- May 2016
- Case
AbbVie
By: Kevin Schulman, Laura Little, Samyukta Mullangi and Stephen Schleicher
This case focuses on the impact of a novel regulatory pathway, the biosimilars pathway, on the strategy of a major pharmaceutical firm that finds its largest product (60% of revenue) at risk. The case reviews the rationale for the pathway, the emerging biosimilars... View Details
- December 2012 (Revised August 2013)
- Case
BMS-Biocon Research Center: Growing a Joint Research Venture in India
By: Vicki Sato, Sen Chai, Rich Ballenger, Christine Chi, Alexander Down and Ross Leimberg
Bristol Myers Squibb, a multi-national pharmaceutical company, is seeking to globalize its R&D strategy while managing costs. It has formed a joint venture with an Indian company, which has worked well, but now faces a strategic decision on how and whether to continue. View Details
Keywords: Pharmaceuticals; Global Innovation; Research And Development; Biomedical Research; Joint Ventures; India; United States
Sato, Vicki, Sen Chai, Rich Ballenger, Christine Chi, Alexander Down, and Ross Leimberg. "BMS-Biocon Research Center: Growing a Joint Research Venture in India." Harvard Business School Case 613-072, December 2012. (Revised August 2013.)
- June 9, 2023
- Article
A Radical Treatment for Insulin Pricing
By: Leemore S. Dafny
In 2021, the Food and Drug Administration (FDA) approved the first interchangeable biosimilar for long-acting insulin, which many hoped would be substantially cheaper than the reference branded product. I explain why prices have barely changed, and argue that a... View Details
Keywords: Biosimilars; Rebates; Pharmaceuticals; Health Care and Treatment; Price; Governing Rules, Regulations, and Reforms; Pharmaceutical Industry; United States
Dafny, Leemore S. "A Radical Treatment for Insulin Pricing." New England Journal of Medicine 386, no. 23 (June 9, 2023): 2157–2159.
- April 2017
- Case
Imprimis (A)
By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel
This case examines the strategic choices and evolving business model of Imprimis Pharmaceuticals from the perspective of CEO Mark Baum. The (A) case provides a brief history of the company and of the compounding business, outlining the challenges faced by Imprimis in... View Details
Keywords: Strategy; Healthcare; Drug Compounding; Pharmaceuticals; Compounding; Drug Development; Decision-making; Mark Baum; Imprimis; Small Business; Decisions; Cost vs Benefits; Business Strategy; Business Model; Decision Choices and Conditions; Pharmaceutical Industry; United States
Casadesus-Masanell, Ramon, Karen Elterman, and Marc Appel. "Imprimis (A)." Harvard Business School Case 717-426, April 2017.
- November 2016
- Supplement
Alnylam Pharmaceuticals: Building Value from the IP Estate (B)
By: Vicki Sato, Willy Shih and Matt Higgins
The leader of a pioneering biotech company in the siRNA space weighs his options for scaling production capacity in advance of an anticipated commercial launch. Operational complexity and relative merits of in-house manufacturing versus a contractor model are... View Details
Keywords: Pharmaceutical Companies; Pharmaceutical Industry; Biotech; Biotechnology; Operational Complexity; Strategy; Manufacturing; Production; Strategic Planning; Intellectual Property; Biotechnology Industry; United States
Sato, Vicki, Willy Shih, and Matt Higgins. "Alnylam Pharmaceuticals: Building Value from the IP Estate (B)." Harvard Business School Supplement 617-022, November 2016.
- June 2017
- Supplement
Transformation at Eli Lilly & Co. (C)
By: William R. Kerr and Alexis Brownell
Keywords: Eli Lilly; Pharmaceutical Companies; Restructuring; Organizational Change and Adaptation; Pharmaceutical Industry; Indiana; Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (C)." Harvard Business School Supplement 817-137, June 2017.
- June 2017
- Supplement
Transformation at Eli Lilly & Co. (B)
By: William R. Kerr and Alexis Brownell
Keywords: Eli Lilly; Pharmaceutical Companies; Restructuring; Organizational Change and Adaptation; Pharmaceutical Industry; Indiana; Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (B)." Harvard Business School Supplement 817-136, June 2017.